- Home
- JZXN vs KZIA Comparison
JZXN vs KZIA Comparison
Compare JZXN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JZXN | KZIA |
|---|---|---|
| Founded | 2019 | 1994 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 16.6M |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | JZXN | KZIA |
|---|---|---|
| Price | $0.18 | $15.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 1.4M | ★ 1.9M |
| Earning Date | 03-05-2026 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $97,465.00 | ★ $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $2.86 |
| 52 Week High | $7.82 | $23.60 |
Technical Indicators
Market Signals| Indicator | JZXN | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 32.56 | 72.51 |
| Support Level | $0.16 | $7.68 |
| Resistance Level | $0.20 | $16.25 |
| Average True Range (ATR) | 0.02 | 2.11 |
| MACD | 0.01 | 0.66 |
| Stochastic Oscillator | 19.25 | 88.76 |
Price Performance
Historical ComparisonAbout JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its operating segments are propretaey product; and resale of sourced Equipment and accessories from third party products. The company generates a majority of its revenue from the propretaey product segment. Geographically, the firm operates in China.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.